Literature DB >> 11033059

Neurotensin: peptide for the next millennium.

B M Tyler-McMahon1, M Boules, E Richelson.   

Abstract

Neurotensin is an endogenous tridecapeptide neurotransmitter (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Try-Ile-Leu-OH) that was discovered by Carraway and Leeman in bovine hypothalami in the early 1970s. Since then this peptide has been the subject of a multitude of articles detailing discoveries related to its activity, receptors, localization, synthesis, and interactions with other systems. This review article does not intend to summarize again all the history of this fascinating peptide and its receptors, since this has been done quite well by others. The reader will be directed to these other reviews, where appropriate. Instead, this review attempts to provide a summary of current knowledge about neurotensin, why it is an important peptide to study, and where the field is heading. Special emphasis is placed on the behavioral studies, particularly with reference to agonists, antagonists, and antisense studies, as well as, the interaction of neurotensin with other neurotransmitters.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11033059     DOI: 10.1016/s0167-0115(00)00183-x

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  41 in total

Review 1.  Different neuronal phenotypes in the lateral hypothalamus and their role in sleep and wakefulness.

Authors:  Dmitry Gerashchenko; Priyattam J Shiromani
Journal:  Mol Neurobiol       Date:  2004-02       Impact factor: 5.590

2.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

3.  Increased ethanol consumption and preference in mice lacking neurotensin receptor type 2.

Authors:  Moonnoh R Lee; David J Hinton; Sencan S Unal; Elliott Richelson; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

4.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

5.  Revisiting the structure of the Vps10 domain of human sortilin and its interaction with neurotensin.

Authors:  Esben M Quistgaard; Morten K Grøftehauge; Peder Madsen; Lone T Pallesen; Brian Christensen; Esben S Sørensen; Poul Nissen; Claus M Petersen; Søren S Thirup
Journal:  Protein Sci       Date:  2014-07-22       Impact factor: 6.725

6.  Neurotensinergic Excitation of Dentate Gyrus Granule Cells via Gαq-Coupled Inhibition of TASK-3 Channels.

Authors:  Haopeng Zhang; Hailong Dong; Nicholas I Cilz; Lalitha Kurada; Binqi Hu; Etsuko Wada; Douglas A Bayliss; James E Porter; Saobo Lei
Journal:  Cereb Cortex       Date:  2014-11-18       Impact factor: 5.357

7.  Neurotensinergic augmentation of glutamate release at the perforant path-granule cell synapse in rat dentate gyrus: Roles of L-Type Ca²⁺ channels, calmodulin and myosin light-chain kinase.

Authors:  Haopeng Zhang; Hailong Dong; Saobo Lei
Journal:  Neuropharmacology       Date:  2015-04-02       Impact factor: 5.250

8.  Systemically and topically active antinociceptive neurotensin compounds.

Authors:  Grace C Rossi; Joshua E Matulonis; Elliott Richelson; Denise Barbut; Gavril W Pasternak
Journal:  J Pharmacol Exp Ther       Date:  2010-06-24       Impact factor: 4.030

Review 9.  Peptide-based imaging agents for cancer detection.

Authors:  Xiaolian Sun; Yesen Li; Ting Liu; Zijing Li; Xianzhong Zhang; Xiaoyuan Chen
Journal:  Adv Drug Deliv Rev       Date:  2016-06-18       Impact factor: 15.470

10.  Responses of the rat basal ganglia neurotensin systems to low doses of methamphetamine.

Authors:  Mario E Alburges; Amanda J Hoonakker; Nathaniel M Cordova; Christina M Robson; Lisa M McFadden; Amber L Martin; Glen R Hanson
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.